STAT+: Will Novo Nordisk’s slashing of obesity drug prices save patients’ money? It depends
Stat News • 2/24/2026
Summary
Novo Nordisk has slashed prices of its obesity drugs. Whether this will save patients money or expand access is uncertain.
Advertisement
Lindy Score Breakdown (V4.2)
47d
Age
1
Sources
from cluster
1133
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1133/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1133/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 47 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about cheap generic obesity drugs in India, high demand for estrogen patches and more
Stat News • 2 days ago
STAT+: A new trick for old science, and biotech VCs’ scrambled playbook
Stat News • 2 days ago
STAT+: GSK says goodbye to leucovorin (again)
Stat News • 2 days ago
STAT+: Up and down the ladder: The latest comings and goings
Stat News • 2 days ago
Opinion: What STAT readers think about nutrition education in med school
Stat News • 1 day ago
Opinion: What public health can learn from the MAHA movement
Stat News • 2 days ago
Opinion: Sports betting is creating a twofold public health crisis for some young men
Stat News • 1 day ago
Opinion: I’m a MAHA activist. I went into the public health lion’s den — and it changed how I think
Stat News • 2 days ago
GAO report shows gap between scale of illegal vapes and enforcement
Stat News • 2 days ago